These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 26835543)

  • 1. ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.
    Vergès B; Adiels M; Boren J; Barrett PH; Watts GF; Chan D; Duvillard L; Söderlund S; Matikainen N; Kahri J; Lundbom N; Lundbom J; Hakkarainen A; Aho S; Simoneau-Robin I; Taskinen MR
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1398-406. PubMed ID: 26835543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.
    Vergès B; Adiels M; Boren J; Barrett PH; Watts GF; Chan D; Duvillard L; Söderlund S; Matikainen N; Kahri J; Robin I; Taskinen MR
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4281-90. PubMed ID: 25077901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.
    Ooi EM; Watts GF; Chan DC; Nielsen LB; Plomgaard P; Dahlbäck B; Barrett PH
    Atherosclerosis; 2010 May; 210(1):326-30. PubMed ID: 20031132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes.
    Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM
    Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL-apoA-I kinetics in response to 16 wk of exercise training in men with nonalcoholic fatty liver disease.
    Whyte MB; Shojaee-Moradie F; Sharaf SE; Cuthbertson DJ; Kemp GJ; Barrett M; Jackson NC; Herring RA; Wright J; Thomas EL; Bell J; Umpleby AM
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E839-E847. PubMed ID: 32286882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin is an important determinant of apoA-I catabolism.
    Vergès B; Petit JM; Duvillard L; Dautin G; Florentin E; Galland F; Gambert P
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1364-9. PubMed ID: 16574896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men.
    Chan DC; Watts GF; Ooi EM; Chan DT; Wong AT; Barrett PH
    Metabolism; 2011 Oct; 60(10):1482-7. PubMed ID: 21550083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
    Millar JS; Duffy D; Gadi R; Bloedon LT; Dunbar RL; Wolfe ML; Movva R; Shah A; Fuki IV; McCoy M; Harris CJ; Wang MD; Howey DC; Rader DJ
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):140-6. PubMed ID: 18988892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.
    Ng TW; Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2009 Oct; 118(1):79-85. PubMed ID: 19456294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
    Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study.
    Pont F; Duvillard L; Florentin E; Gambert P; Vergès B
    Int J Obes Relat Metab Disord; 2002 Sep; 26(9):1151-8. PubMed ID: 12187390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein.
    Rader DJ; Schäfer J; Lohse P; Verges B; Kindt M; Zech LA; Steinmetz A; Brewer HB
    J Clin Invest; 1993 Aug; 92(2):1009-17. PubMed ID: 8349786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men.
    Wong AT; Chan DC; Ooi EM; Ng TW; Watts GF; Barrett PH
    Clin Sci (Lond); 2013 Mar; 125(1):45-51. PubMed ID: 23356247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL.
    Golay A; Zech L; Shi MZ; Chiou YA; Reaven GM; Chen YD
    J Clin Endocrinol Metab; 1987 Sep; 65(3):512-8. PubMed ID: 3114304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.